A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)

A Multicenter, Randomized, Parallel-group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 mg Once Daily Versus Diclofenac Sodium 75 mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00140972

Enrollment

160

Registered

2005-09-01

Start date

2004-12-03

Completion date

2005-06-27

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Arcoxia

Brief summary

A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip

Interventions

DRUGMK0663; etoricoxib / Duration of Treatment:4 Weeks

DRUGComparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Chinese males or females at least 40 years of age with osteoarthritis of the knee or hip

Design outcomes

Primary

Measure	Time frame
WOMAC pain subscale	—

Secondary

Measure	Time frame
WOMAC Physical function subscale; WOMAC Stiffness subscale; Patient Global Assessment of Response to Therapy; Investigator Global Assessment of Disease Status	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026